Optimization of Cervical Cancer Screening Among Women Living With HIV in Latin American Countries
Cervix Cancer, HPV Infection, Cervical High Grade Squamous Intraepithelial Lesion
About this trial
This is an interventional diagnostic trial for Cervix Cancer focused on measuring HPV, cervical cancer screening, women with HIV, DNA methylation, extended HPV genotyping
Eligibility Criteria
Inclusion Criteria HIV-1 infection, as documented by 1) any FDA approved, licensed HIV rapid test performed in conjunction with screening (oral immunoblot, enzyme-linked immunoassay-ELISA, test kit, and confirmed by Western blot or other approved test), OR 2) a physician's written record that documents HIV infection with supporting information on the participant's relevant medical history and/or current management of HIV infection, OR 3) documentation of a prescription of an approved antiretroviral regimen by either possession of pill bottles or packages with prescriber's name or antiretrovirals (ARVs) dispensed from an HIV clinical treatment program with two participant identifiers affixed to the bottles or packages. Cisgender women or transgender men. Aged 25 to 65. Ability to understand and the willingness to sign a written informed consent document by the participant or by the legal representative(s) of the participant. Exclusion Criteria History of cervical, vulvar, vaginal, perianal, anal cancer or oral cancer. Have undergone cervical cancer screening in the last 6 months. Have undergone cervical HSIL treatment in the past year. Have a history of hysterectomy with removal of the cervix. Have never had sexual intercourse (oral or genital or anal). Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (including opportunistic infections of Acquired Immunodeficiency Syndrome-AIDS and/or genitourinary infections), symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements. Pregnant women are excluded from this study due to the lack of safety data of performing colposcopy during pregnancy. Any other medical condition or social situation that would put the participant, the study staff, or the study outcomes at risk, as determined by the site investigators.
Sites / Locations
- University of São PauloRecruiting
- National Institute of Public Health, Mexico
Arms of the Study
Arm 1
Experimental
Cervical cancer screening (single arm)
Women will be screened for cervical cancer with HPV testing that provides extended genotyping and DNA quantification. Women will also provide other samples for cervical cancer screening tests. Women will under cervical biopsies.